immunity News and Research

RSS

Brazilian coronavirus variant could pose a bigger threat than previously assumed

A new study with the University of Copenhagen represented indicates that the coronavirus variant called P.1, which originated in Brazil, could pose a bigger threat than previously assumed.

28 Apr 2021

Study examines mRNA COVID-19 vaccine’s effectiveness across age and gender

The findings reveal that although the two-dose vaccine regimen initially induces robust antibody response in all age groups, older male individuals are particularly associated with a gradual decline in vaccine-induced immunity six weeks after the second vaccine dose.

28 Apr 2021

Peptide nucleocapsid vaccine candidate elicits protective T cell immunity against SARS-CoV-2 in vivo

A new study describes a synthetic peptide used as a platform to generate protective adaptive cellular immunity to the virus in rhesus macaques, which are the gold standard for preclinical testing in humans.

28 Apr 2021

Ohio’s Amish suffered a lot from Covid, but vaccines are still a hard sell

The Amish communities of northeastern Ohio engage in textbook communal living. Families eat, work and go to church together, and through the pandemic, mask-wearing and physical distancing have been spotty. That has meant that these communities bore a high rate of infection and death.

28 Apr 2021

You don’t have to suffer to benefit from Covid vaccination — but some prefer it

If you think vaccination is an ordeal now, consider the 18th-century version. After having pus from a smallpox boil scratched into your arm, you would be subject to three weeks of fever, sweats, chills, bleeding and purging with dangerous medicines, accompanied by hymns, prayers and hell-fire sermons by dour preachers.

28 Apr 2021

First-of-its-kind method cryopreserves fruit fly embryos in liquid nitrogen

Cryopreservation, or the long-term storage of biomaterials at ultralow temperatures, has been used across cell types and species.

28 Apr 2021

Scientists identify blood cells most likely to be targeted by HIV during a real-life infection

In the 40-some years since the beginning of the HIV/AIDS epidemic, scientists have learned a lot about the virus, the disease, and ways to treat it. But one thing they still don't completely understand is which exact cells are most susceptible to HIV infection.

28 Apr 2021

SARS-CoV-2 recruits heme metabolites in antibody evasion

A research paper recently published in the journal Science Advances by Cherepanov et al. (April 22nd, 2021) demonstrated that the NTD binds to biliverdin, a product of heme catabolism, leading to enhanced antibody escape at physiologically relevant concentrations.

28 Apr 2021

Nucleocapsid-based vaccines may prevent SARS-CoV-2 dissemination to distal organs

A team of scientists recently investigated and compared the efficacy of spike-based and nucleocapsid-based COVID-19 vaccines in mice infected with SARS-CoV-2. Their findings reveal that nucleocapsid-based vaccines are effective in preventing SARS-CoV-2 infection in distal organs, such as the brain.

27 Apr 2021

First cases of B.1.1.7 variant with E484K mutation in Pennsylvania

The E484K mutation has also been found on the B.1.351 and P.1 variant, contributing to their status as variants of concern. In February 2021, Public Health England published a report of 11 B.1.1.7 genomes that also had the E484K spike mutation. Currently, there are 247 isolates of B.1.1.7 + E484K reported globally, and new research finds the first reports of it in southeastern Pennsylvania.

27 Apr 2021

Triple mutation in SARS-CoV-2 seen in second wave of COVID-19 in India

Researchers sequenced the viral genome from samples in the state of Maharashtra and found a unique combination of three mutations that suggest the SARS-CoV-2 virus is continually evolving to evade the human immune response.

27 Apr 2021

Prior SARS-CoV-2 infection and Pfizer-BioNTech’s COVID-19 vaccine provide similar immunity

Researchers in Israel have conducted a study showing that the immunity provided against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease (COVID-19) – is similar following natural infection or immunization with the Pfizer-BioNTech BNT162b2 vaccine.

26 Apr 2021

Commonly-prescribed drug for IBD blunts COVID-19 vaccine response

People who take a commonly-prescribed drug for inflammatory bowel disease (IBD) should not assume they are protected after a first dose of COVID-19 vaccine, after a large-scale study found many had poor antibody responses.

26 Apr 2021

SARS-CoV-2 antibody response robust in nursing home residents after Pfizer-BioNTech vaccine

However, with the waning of the immune response, it is not clear if these older people respond to the vaccine as well as younger individuals do. A recent study explored this question and found that though the antibody levels were somewhat lower in this group, they were still robust. This is a promising observation.

26 Apr 2021

Previous SARS-CoV-2 infection associated with more adverse events following mRNA vaccination

The phase 3 trials of the Pfizer and Moderna COVID-19 vaccines did not include those with a known previous SARS-CoV-2 infection. Recent evidence indicates that mRNA vaccines may induce more adverse events in these individuals. In a recent study, 947 individuals, 265 of which have previously reported SARS-CoV-2 infection, were monitored post-vaccination for adverse events, finding that there could be a link between previous infection and greater incidence of these events.

26 Apr 2021

Single dose of J&J's Ad26.COV2.S vaccine effective against SARS-CoV-2 including in South Africa variant

One of these vaccines, the Ad26.COV2.S vaccine by Johnson & Johnson and Janssen, is a recombinant, replication-incompetent human adenovirus type 26 vector that encodes full-length SARS-CoV-2 spike protein in a prefusion-stabilized conformation.

26 Apr 2021

Potential new COVID vaccine from Australia

Phase 1 trial results published in The Lancet Infectious Diseases found a new subunit vaccine —an MF59-adjuvanted subunit vaccine using recombinant spike glycoprotein stabilized in a prefusion conformation by a novel molecular clamp — targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was safe and effective in producing an antigen-specific response in healthy adults.

26 Apr 2021

The potential of CRISPR-based diagnostic assays and treatment approaches against COVID-19

In their review paper recently published in the Indian Journal of Clinical Biochemistry, a group of authors discusses currently available and forthcoming CRISPR-based diagnostic assays, as well as the possibility of using the CRISPR/Cas system as a salient treatment or prevention strategy in the fight against coronavirus disease 2019 (COVID-19).

25 Apr 2021

A detailed look at two cases of symptomatic COVID in vaccinated individuals

In a recent brief report published in the prestigious New England Journal of Medicine, researchers from the Rockefeller University in New York described a case of two fully vaccinated individuals in whom they found subsequent breakthrough infections with variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), carrying a number of substitutions of interest.

25 Apr 2021

Single dose of Pfizer-BioNTech COVID-19 vaccine induces immunity in CML patients

Researchers in the UK have shown that a single dose of the Pfizer-BioNTech vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induced antibody and cellular responses in patients with chronic myeloid leukemia (CML) who were taking tyrosine kinase inhibitors.

25 Apr 2021

immunity News and Research

Brazilian coronavirus variant could pose a bigger threat than previously assumed

Study examines mRNA COVID-19 vaccine’s effectiveness across age and gender

Peptide nucleocapsid vaccine candidate elicits protective T cell immunity against SARS-CoV-2 in vivo

Ohio’s Amish suffered a lot from Covid, but vaccines are still a hard sell

You don’t have to suffer to benefit from Covid vaccination — but some prefer it

First-of-its-kind method cryopreserves fruit fly embryos in liquid nitrogen

Scientists identify blood cells most likely to be targeted by HIV during a real-life infection

SARS-CoV-2 recruits heme metabolites in antibody evasion

Nucleocapsid-based vaccines may prevent SARS-CoV-2 dissemination to distal organs

First cases of B.1.1.7 variant with E484K mutation in Pennsylvania

Triple mutation in SARS-CoV-2 seen in second wave of COVID-19 in India

Prior SARS-CoV-2 infection and Pfizer-BioNTech’s COVID-19 vaccine provide similar immunity

Commonly-prescribed drug for IBD blunts COVID-19 vaccine response

SARS-CoV-2 antibody response robust in nursing home residents after Pfizer-BioNTech vaccine

Previous SARS-CoV-2 infection associated with more adverse events following mRNA vaccination

Single dose of J&J's Ad26.COV2.S vaccine effective against SARS-CoV-2 including in South Africa variant

Potential new COVID vaccine from Australia

The potential of CRISPR-based diagnostic assays and treatment approaches against COVID-19

A detailed look at two cases of symptomatic COVID in vaccinated individuals

Single dose of Pfizer-BioNTech COVID-19 vaccine induces immunity in CML patients

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News